282
Participants
Start Date
October 21, 2011
Primary Completion Date
June 19, 2015
Study Completion Date
June 19, 2015
Boceprevir (BOC)
200 mg capsules, 800 mg three times daily by mouth
Placebo to boceprevir
200 mg placebo capsules, 800 mg three times daily by mouth
Peginterferon alfa-2b (PEG)
1.5 mcg/kg/week subcutaneously
Ribavirin (RBV)
200 mg capsules, weight-based dosing 800 to 1400 mg/day by mouth divided twice daily
Cross-Over Boceprevir Treatment
At Treatment Week 14, participants in the Placebo group with detectable HCV-RNA at Treatment Week 12 have the option to add boceprevir 800 mg three times daily to the PEG + RBV regimen for up to 32 weeks.
Merck Sharp & Dohme LLC
INDUSTRY